Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link When will the FDA reclassify BPC 157 to Category 1 Octagon AI The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Are Peptides coming off of the FDA Category 2 list? A legal breakdown.